Abbott Laboratories (ABT) 40.63 $ABT
Express Scripts Includes Praluent and Repatha in Formulary
Zacks Equity Research - Zacks Investment Research - 1 hr 56 mins ago
Pharmacy benefit manager Express Scripts (ESRX) announced that it will include two new cholesterol-lowering drugs -- Regeneron/Sanofi's (REGN/SNY) Praluent and Amgen's (AMGN) Repatha -- on its National Preferred Formulary.
ABT: 40.63 (+0.74), ESRX: 82.57 (+1.27), AMGN: 148.05 (+6.83), SNY: 48.33 (-0.61), REGN: 485.76 (+25.94)
AmerisourceBergen (ABC) Acquires PharMEDium for $2.6B
Zacks Equity Research - Zacks Investment Research - 2 hrs 44 mins ago
AmerisourceBergen (ABC) signed a definitive agreement to acquire privately held PharMEDium Healthcare Holdings, Inc. from Clayton, Dubilier & Rice for $2.6 billion in cash.
ABT: 40.63 (+0.74), ABC: 92.94 (-0.09), MCK: 184.98 (+0.98), CAH: 77.55 (-0.56)
Kentucky pharmacy PharMerica agrees to $9.25M settlement
AP - Wed Oct 07, 2:16PM CDT
RICHMOND, Va. (AP) — A Kentucky pharmacy has agreed to pay $9.25 million to settle allegations that it solicited and received kickbacks from a manufacturer in exchange for promoting a drug with nursing home patients, federal prosecutors announced Wednesday.
ABT: 40.63 (+0.74)
Publicly Traded Long Term Care Pharmacy - PharMerica Corp. - Settles False Claims Allegations
PR Newswire - Wed Oct 07, 2:08PM CDT
Long Term Care Pharmacy - PharMerica Corp.- has agreed to pay $9.25 million to settle allegations that it violated the federal false claims act and similar state false claims acts by receiving kickbacks from Abbott Laboratories to promote the anti-epileptic drug, Depakote.
PMC: 28.02 (+0.78), ABT: 40.63 (+0.74)
Abbott (ABT) Stock Rises on Barclays Upgrade
at The Street - Wed Oct 07, 9:16AM CDT
Abbott (ABT) stock is higher after it was upgraded to ‘overweight’ from ‘equal weight’ at Barclays.
ABT: 40.63 (+0.74)
2 ETFs Rising to Rank #1 This Earnings Season
Sweta Killa - Zacks Investment Research - Wed Oct 07, 9:15AM CDT
A couple of sector ETFs have seen their Ranks surging to the top hierarchy and could be the winners this earnings season.
ABT: 40.63 (+0.74), MDT: 70.94 (+1.02), ORLY: 251.78 (-2.01), IHI: 113.65 (+1.43), PEZ: 46.12 (+0.23)
Analysts' Actions -- Tesla, Abbott, Morgan Stanley, Yum
at The Street - Wed Oct 07, 7:41AM CDT
Here are Wednesday's top research calls, including ratings or estimate changes at Tesla, Abbott, Morgan Stanley and Yum
TSLA: 231.96 (-9.50), CME: 90.69 (+0.84), ABT: 40.63 (+0.74), MJN: 72.35 (-2.74), ADBE: 80.65 (-4.50), YUM: 67.71 (-15.71), MS: 32.93 (+0.57)
Upgrade Alert for Abbott Laboratories (ABT)
Comtex SmarTrend(R) - Wed Oct 07, 7:07AM CDT
Abbott Laboratories (NYSE:ABT) was upgraded from Equal Weight to Overweight at Barclays Capital today. The stock closed yesterday at $39.89 on volume of 11.7 million shares, above average daily volume of 8.7 million. Potential upside of 39.6% exists for Abbott Laboratories, based on a current level of $39.89 and analysts' average consensus price target of $55.68. Abbott Laboratories shares should first meet resistance at the 50-day moving average (MA) of $45.61 and find additional resistance at the 200-day MA of $46.86.
ABT: 40.63 (+0.74)
Global Diabetes Care Devices Market Outlook 2015-2020 - Market is Expected to Grow at a CAGR of 5.2%
M2 - Wed Oct 07, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb8dxs/global_diabetes) has announced the addition of the "Global Diabetes Care Devices Market Outlook: 2015-2020" report to their offering. The global diabetes care devices market is expected to grow at a CAGR of 5.2% from 2015 to 2020 to reach $24.6 billion by 2020 This market is mainly driven by increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle and improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes. Furthermore, huge investments by the market leaders and foraying of new companies into this market, wide scope of penetration in untapped and emerging markets, and rising awareness among people about diabetes care are also accelerating the growth of this market. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, lack of awareness, strict regulatory obligations, and high cost of diabetic food hinders the growth of this market to some extent. The research report on the diabetes care devices market provides comprehensive analysis of the global market with a country level analysis and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major product segments such as diabetes control solutions, diabetes monitoring devices, and insulin delivery devices. The diabetes monitoring devices segment further sub-segmented into continuous blood glucose monitoring devices, test strips, lancets, and hemoglobin A1c (HbA1c) testing kits. The insulin delivery devices further sub-segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. Key Topics Covered: 1 Introduction to Diabetes Care Devices Market 2 Executive Summary 3 Market Insights 4 Global Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Product Type 5 Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Geography 6 Global Diabetes Care Devices Market- Competitive Landscape 7 Company Profiles - ARKRAY Inc. - Abbott Laboratories - Bayer HealthCare AG - Becton, Dickinson and Company - Dexcom, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Medtronic, Inc. - Novo Nordisk A/S - Sanofi S.A - Tandem Diabetes Care, Inc - Terumo Corporation - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/jb...l_diabetes
JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), NVO: 54.60 (-0.59), MDT: 70.94 (+1.02), LLY: 83.99 (-0.18)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Boston Scientific's Bioabsorbable Stent Wins FDA Approval
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:05PM CDT
According to Boston Scientific (BSX), this launch will be a significant milestone in the history of stent technology evolution.
BSX: 16.82 (+0.25), ICUI: 106.89 (+1.05), ABT: 40.63 (+0.74), ENZY: 9.67 (+0.34), NUVA: 52.21 (+0.14)
Look for Shares of Abbott Laboratories to Potentially Rebound after Yesterday's 3.62% Sell Off
Comtex SmarTrend(R) - Tue Oct 06, 4:00PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.28 to a high of $41.34. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $40.17 on volume of 11.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 40.63 (+0.74)
Valeant Shares Down 37% since August; More Pain Ahead?
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 3:30PM CDT
Shares of Valeant Pharmaceuticals (VRX) have plummeted around 37% in the last two months.
ABT: 40.63 (+0.74), VRX: 169.83 (+3.83), ESRX: 82.57 (+1.27), ABBV: 55.63 (+0.55)
Engaged Capital Pressures HeartWare to Drop Valtech Deal
at The Street - Tue Oct 06, 9:11AM CDT
The activist investor is calling for the end of the proposed $860 million deal, vowing to campaign against it and seek board seats if its advice goes unheeded.
BSX: 16.82 (+0.25), ABT: 40.63 (+0.74), JNJ: 94.98 (+1.56), BDX: 137.24 (+2.65), ZBH: 94.89 (+0.90), MDT: 70.94 (+1.02), STJ: 63.10 (+0.62), HTWR: 54.41 (+2.10)
Abbott Laboratories (ABT) Breaks Through Support at $41.01
Comtex SmarTrend(R) - Tue Oct 06, 9:04AM CDT
Abbott Laboratories (NYSE:ABT) has opened bearishly below the pivot of $41.39 today and has reached the first level of support at $41.01. Investors may be interested in a cross of the next downside pivot targets of $40.63 and $39.87.
ABT: 40.63 (+0.74)
2016 Emerging Clinical Chemistry and Immunodiagnostic Technologies, and Strategic Profiles of Leading Suppliers
M2 - Tue Oct 06, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl2tmx/2016_emerging) has announced the addition of the "2016 Emerging Clinical Chemistry and Immunodiagnostic Technologies, and Strategic Profiles of Leading Suppliers" report to their offering. This 145-page report reviews potential market applications of current and emerging clinical chemistry and immunodiagnostic technologies, including monoclonal and polyclonal antibodies, immunoassays, IT, dry chemistry, biosensors, robotics, molecular diagnostics and others. The report also presents strategic assessments of current and emerging suppliers of clinical chemistry and immunodiagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott Laboratories - AdnaGen/Alere - Agilent Technologies - Bayer Healthcare - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio - Grifols - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/sl...6_emerging
ABT: 40.63 (+0.74), A: 35.54 (+0.64), DGX: 62.68 (+1.10), DHR: 88.44 (+1.21)
2015 Clinical Chemistry Laboratory and POC Instrumentation Review: Immunodiagnostic Analyzers and Strategic Profiles of Leading Suppliers
M2 - Tue Oct 06, 7:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmb7rq/2015_clinical) has announced the addition of the "2015 Clinical Chemistry Laboratory and POC Instrumentation Review: Immunodiagnostic Analyzers and Strategic Profiles of Leading Suppliers" report to their offering. This 68-page report reviews operating characteristics and features of high, medium, and low-volume/POC clinical chemistry and immunodiagnostic systems. The report also presents strategic assessments of current and emerging suppliers of clinical chemistry and immunodiagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott Laboratories - AdnaGen/Alere - Agilent Technologies - Bayer Healthcare - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio - Grifols - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/hm...5_clinical
ABT: 40.63 (+0.74), A: 35.54 (+0.64), DGX: 62.68 (+1.10), DHR: 88.44 (+1.21)
2016 Emerging Clinical Chemistry and Immunodiagnostic Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers
M2 - Tue Oct 06, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wt5pfk/2016_emerging) has announced the addition of the "2016 Emerging Clinical Chemistry and Immunodiagnostic Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers" report to their offering. This 320-page report presents an overview of the clinical significance and market needs for major Chemistry, TDM, Endocrine, Cancer, Immunoprotein, and Abused Drug assays, including listings of companies developing or marketing new technologies and products. The report also presents strategic assessments of current and emerging suppliers of clinical chemistry and immuno-diagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott Laboratories - AdnaGen/Alere - Agilent Technologies - Bayer Healthcare - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio - Grifols - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/wt...6_emerging
ABT: 40.63 (+0.74), A: 35.54 (+0.64), DGX: 62.68 (+1.10), DHR: 88.44 (+1.21)
Amicus Therapeutics Plunges on Delay in NDA Submission
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 5:20PM CDT
Shares of Amicus Therapeutics (FOLD) plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat).
ABT: 40.63 (+0.74), SHPG: 201.88 (-1.89), SNY: 48.33 (-0.61), FOLD: 7.01 (+0.71)
Express Scripts Includes Praluent and Repatha in Formulary
Zacks Equity Research - Zacks Investment Research - 1 hr 56 mins ago
Pharmacy benefit manager Express Scripts (ESRX) announced that it will include two new cholesterol-lowering drugs -- Regeneron/Sanofi's (REGN/SNY) Praluent and Amgen's (AMGN) Repatha -- on its National Preferred Formulary.
ABT: 40.63 (+0.74), ESRX: 82.57 (+1.27), AMGN: 148.05 (+6.83), SNY: 48.33 (-0.61), REGN: 485.76 (+25.94)
AmerisourceBergen (ABC) Acquires PharMEDium for $2.6B
Zacks Equity Research - Zacks Investment Research - 2 hrs 44 mins ago
AmerisourceBergen (ABC) signed a definitive agreement to acquire privately held PharMEDium Healthcare Holdings, Inc. from Clayton, Dubilier & Rice for $2.6 billion in cash.
ABT: 40.63 (+0.74), ABC: 92.94 (-0.09), MCK: 184.98 (+0.98), CAH: 77.55 (-0.56)
Kentucky pharmacy PharMerica agrees to $9.25M settlement
AP - Wed Oct 07, 2:16PM CDT
RICHMOND, Va. (AP) — A Kentucky pharmacy has agreed to pay $9.25 million to settle allegations that it solicited and received kickbacks from a manufacturer in exchange for promoting a drug with nursing home patients, federal prosecutors announced Wednesday.
ABT: 40.63 (+0.74)
Publicly Traded Long Term Care Pharmacy - PharMerica Corp. - Settles False Claims Allegations
PR Newswire - Wed Oct 07, 2:08PM CDT
Long Term Care Pharmacy - PharMerica Corp.- has agreed to pay $9.25 million to settle allegations that it violated the federal false claims act and similar state false claims acts by receiving kickbacks from Abbott Laboratories to promote the anti-epileptic drug, Depakote.
PMC: 28.02 (+0.78), ABT: 40.63 (+0.74)
Abbott (ABT) Stock Rises on Barclays Upgrade
at The Street - Wed Oct 07, 9:16AM CDT
Abbott (ABT) stock is higher after it was upgraded to ‘overweight’ from ‘equal weight’ at Barclays.
ABT: 40.63 (+0.74)
2 ETFs Rising to Rank #1 This Earnings Season
Sweta Killa - Zacks Investment Research - Wed Oct 07, 9:15AM CDT
A couple of sector ETFs have seen their Ranks surging to the top hierarchy and could be the winners this earnings season.
ABT: 40.63 (+0.74), MDT: 70.94 (+1.02), ORLY: 251.78 (-2.01), IHI: 113.65 (+1.43), PEZ: 46.12 (+0.23)
Analysts' Actions -- Tesla, Abbott, Morgan Stanley, Yum
at The Street - Wed Oct 07, 7:41AM CDT
Here are Wednesday's top research calls, including ratings or estimate changes at Tesla, Abbott, Morgan Stanley and Yum
TSLA: 231.96 (-9.50), CME: 90.69 (+0.84), ABT: 40.63 (+0.74), MJN: 72.35 (-2.74), ADBE: 80.65 (-4.50), YUM: 67.71 (-15.71), MS: 32.93 (+0.57)
Upgrade Alert for Abbott Laboratories (ABT)
Comtex SmarTrend(R) - Wed Oct 07, 7:07AM CDT
Abbott Laboratories (NYSE:ABT) was upgraded from Equal Weight to Overweight at Barclays Capital today. The stock closed yesterday at $39.89 on volume of 11.7 million shares, above average daily volume of 8.7 million. Potential upside of 39.6% exists for Abbott Laboratories, based on a current level of $39.89 and analysts' average consensus price target of $55.68. Abbott Laboratories shares should first meet resistance at the 50-day moving average (MA) of $45.61 and find additional resistance at the 200-day MA of $46.86.
ABT: 40.63 (+0.74)
Global Diabetes Care Devices Market Outlook 2015-2020 - Market is Expected to Grow at a CAGR of 5.2%
M2 - Wed Oct 07, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb8dxs/global_diabetes) has announced the addition of the "Global Diabetes Care Devices Market Outlook: 2015-2020" report to their offering. The global diabetes care devices market is expected to grow at a CAGR of 5.2% from 2015 to 2020 to reach $24.6 billion by 2020 This market is mainly driven by increasing prevalence of diabetes, technological advancements, rise in obese population, sedentary lifestyle and improper diet, and increasing need for faster and safer diagnosis and treatment of diabetes. Furthermore, huge investments by the market leaders and foraying of new companies into this market, wide scope of penetration in untapped and emerging markets, and rising awareness among people about diabetes care are also accelerating the growth of this market. However, high cost associated with diagnosis and treatment, reimbursement issues for new technologies, lack of awareness, strict regulatory obligations, and high cost of diabetic food hinders the growth of this market to some extent. The research report on the diabetes care devices market provides comprehensive analysis of the global market with a country level analysis and helps in understanding the driving forces for the growth of this market. The report also provides analysis of major product segments such as diabetes control solutions, diabetes monitoring devices, and insulin delivery devices. The diabetes monitoring devices segment further sub-segmented into continuous blood glucose monitoring devices, test strips, lancets, and hemoglobin A1c (HbA1c) testing kits. The insulin delivery devices further sub-segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. Key Topics Covered: 1 Introduction to Diabetes Care Devices Market 2 Executive Summary 3 Market Insights 4 Global Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Product Type 5 Diabetes Care Devices- Market Crackdown ($ Value Analysis), By Geography 6 Global Diabetes Care Devices Market- Competitive Landscape 7 Company Profiles - ARKRAY Inc. - Abbott Laboratories - Bayer HealthCare AG - Becton, Dickinson and Company - Dexcom, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Johnson & Johnson - Medtronic, Inc. - Novo Nordisk A/S - Sanofi S.A - Tandem Diabetes Care, Inc - Terumo Corporation - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/jb...l_diabetes
JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), NVO: 54.60 (-0.59), MDT: 70.94 (+1.02), LLY: 83.99 (-0.18)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Boston Scientific's Bioabsorbable Stent Wins FDA Approval
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:05PM CDT
According to Boston Scientific (BSX), this launch will be a significant milestone in the history of stent technology evolution.
BSX: 16.82 (+0.25), ICUI: 106.89 (+1.05), ABT: 40.63 (+0.74), ENZY: 9.67 (+0.34), NUVA: 52.21 (+0.14)
Look for Shares of Abbott Laboratories to Potentially Rebound after Yesterday's 3.62% Sell Off
Comtex SmarTrend(R) - Tue Oct 06, 4:00PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $39.28 to a high of $41.34. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $40.17 on volume of 11.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 40.63 (+0.74)
Valeant Shares Down 37% since August; More Pain Ahead?
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 3:30PM CDT
Shares of Valeant Pharmaceuticals (VRX) have plummeted around 37% in the last two months.
ABT: 40.63 (+0.74), VRX: 169.83 (+3.83), ESRX: 82.57 (+1.27), ABBV: 55.63 (+0.55)
Engaged Capital Pressures HeartWare to Drop Valtech Deal
at The Street - Tue Oct 06, 9:11AM CDT
The activist investor is calling for the end of the proposed $860 million deal, vowing to campaign against it and seek board seats if its advice goes unheeded.
BSX: 16.82 (+0.25), ABT: 40.63 (+0.74), JNJ: 94.98 (+1.56), BDX: 137.24 (+2.65), ZBH: 94.89 (+0.90), MDT: 70.94 (+1.02), STJ: 63.10 (+0.62), HTWR: 54.41 (+2.10)
Abbott Laboratories (ABT) Breaks Through Support at $41.01
Comtex SmarTrend(R) - Tue Oct 06, 9:04AM CDT
Abbott Laboratories (NYSE:ABT) has opened bearishly below the pivot of $41.39 today and has reached the first level of support at $41.01. Investors may be interested in a cross of the next downside pivot targets of $40.63 and $39.87.
ABT: 40.63 (+0.74)
2016 Emerging Clinical Chemistry and Immunodiagnostic Technologies, and Strategic Profiles of Leading Suppliers
M2 - Tue Oct 06, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl2tmx/2016_emerging) has announced the addition of the "2016 Emerging Clinical Chemistry and Immunodiagnostic Technologies, and Strategic Profiles of Leading Suppliers" report to their offering. This 145-page report reviews potential market applications of current and emerging clinical chemistry and immunodiagnostic technologies, including monoclonal and polyclonal antibodies, immunoassays, IT, dry chemistry, biosensors, robotics, molecular diagnostics and others. The report also presents strategic assessments of current and emerging suppliers of clinical chemistry and immunodiagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott Laboratories - AdnaGen/Alere - Agilent Technologies - Bayer Healthcare - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio - Grifols - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/sl...6_emerging
ABT: 40.63 (+0.74), A: 35.54 (+0.64), DGX: 62.68 (+1.10), DHR: 88.44 (+1.21)
2015 Clinical Chemistry Laboratory and POC Instrumentation Review: Immunodiagnostic Analyzers and Strategic Profiles of Leading Suppliers
M2 - Tue Oct 06, 7:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmb7rq/2015_clinical) has announced the addition of the "2015 Clinical Chemistry Laboratory and POC Instrumentation Review: Immunodiagnostic Analyzers and Strategic Profiles of Leading Suppliers" report to their offering. This 68-page report reviews operating characteristics and features of high, medium, and low-volume/POC clinical chemistry and immunodiagnostic systems. The report also presents strategic assessments of current and emerging suppliers of clinical chemistry and immunodiagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott Laboratories - AdnaGen/Alere - Agilent Technologies - Bayer Healthcare - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio - Grifols - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/hm...5_clinical
ABT: 40.63 (+0.74), A: 35.54 (+0.64), DGX: 62.68 (+1.10), DHR: 88.44 (+1.21)
2016 Emerging Clinical Chemistry and Immunodiagnostic Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers
M2 - Tue Oct 06, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wt5pfk/2016_emerging) has announced the addition of the "2016 Emerging Clinical Chemistry and Immunodiagnostic Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers" report to their offering. This 320-page report presents an overview of the clinical significance and market needs for major Chemistry, TDM, Endocrine, Cancer, Immunoprotein, and Abused Drug assays, including listings of companies developing or marketing new technologies and products. The report also presents strategic assessments of current and emerging suppliers of clinical chemistry and immuno-diagnostic products, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott Laboratories - AdnaGen/Alere - Agilent Technologies - Bayer Healthcare - Beckman Coulter/Danaher - Biomedical Diagnostics - BioMerieux - Bio-Rad - DiaSorin - Eiken - Fujirebio - Grifols - Instrumentation Laboratory - Kyowa Medex - Matritech/Alere - Ortho-Clinical Diagnostics - Quest Diagnostics - Roche - Siemens - Sysmex - Thermo Fisher - Tosoh - Wako - Wallac/PE For more information visit http://www.researchandmarkets.com/research/wt...6_emerging
ABT: 40.63 (+0.74), A: 35.54 (+0.64), DGX: 62.68 (+1.10), DHR: 88.44 (+1.21)
Amicus Therapeutics Plunges on Delay in NDA Submission
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 5:20PM CDT
Shares of Amicus Therapeutics (FOLD) plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat).
ABT: 40.63 (+0.74), SHPG: 201.88 (-1.89), SNY: 48.33 (-0.61), FOLD: 7.01 (+0.71)
